Rohto Pharmaceutical Co.,Ltd. Revises FY2027 Earnings Upward Across All Metrics
Rohto Pharmaceutical Co.,Ltd. (TSE:4527) raised its full-year earnings guidance for the fiscal year ending March 2027, citing stronger-than-expected regional performance and favorable currency adjustments.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue | JPY 369.5bn | JPY 372.3bn | +0.8% |
| Operating Profit | JPY 43.8bn | JPY 45.0bn | +2.7% |
| Ordinary Income | JPY 46.1bn | JPY 47.4bn | +2.8% |
| 親会社株主に帰属する当期純利益 | JPY 34.5bn | JPY 35.2bn | +2.0% |
| 1株当たり当期純利益 | JPY 152.68/share | JPY 155.78/share | +JPY 3.10/share |
The pharmaceutical company attributed the upward revision to two primary factors. First, management adjusted its foreign exchange assumptions, raising the dollar forecast to 158 yen from 155 yen and the Chinese yuan to 23 yen from 22 yen. Second, first-quarter consolidated results exceeded expectations across the Asia, Japan, and Europe segments, signaling robust underlying demand. All profit metrics—operating profit, ordinary income (keijo rieki), and net profit attributable to parent shareholders—are now projected to exceed prior guidance.
The revision underscores Rohto Pharmaceutical’s operational momentum heading into the second half of the fiscal year. Compared to the prior fiscal year, the company expects both revenue growth and profit expansion, with net profit rising 2.0 percent year-over-year. The upward adjustments across operating, ordinary, and bottom-line profitability suggest the company’s core business is performing solidly despite macroeconomic headwinds, while currency tailwinds provide additional support to reported earnings.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.